LABORATORY CORPORATION OF AMERICA HOLDINGS

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and Section 6226 of H.R. 7148, the Consolidated Appropriations Act, 2026, Pub. L. 119-75, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6280/S. 3607, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; S. 3315, the Health Care Cybersecurity and Resiliency Act, provisions relating to cybersecurity; Federal policy relating to access to mandatory code sets for administrative transactions; Federal policy relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.